Difference between revisions of "Agomelatine-hypericum"

From Psychiatrienet
Jump to: navigation, search
 
Line 2: Line 2:
 
| from = agomelatine  
 
| from = agomelatine  
 
| to = hypericum
 
| to = hypericum
| stop = {{StopAgomelatine}}  
+
| stop =  
 +
*'''Day 1:''' Stop agomelatine.
 +
{{StopAgomelatine}}  
 
| start =  
 
| start =  
 +
* ''' Day 2:''' Start administration of hypericum in a dosage of 300 mg three times a day (900 mg/day).
 +
| info =
 
* No wash-out period is necessary.
 
* No wash-out period is necessary.
* Start administration of hypericum the next day in a dosage of 300 mg three times a day (900 mg/day).
 
| info =
 
 
* Hypericum induces the metabolism of agomelatine via CYP1A2.}}
 
* Hypericum induces the metabolism of agomelatine via CYP1A2.}}

Latest revision as of 13:27, 7 October 2015

Agomelatine
Type Antidepressant
Group other
links
ATC-code N06AX22
EMEA valdoxan
PubChem 82148
PubMed Agomelatine
Kompas (Dutch) Agomelatine
Wikipedia Agomelatine
Hypericum
Type Antidepressant
Group other
links
EMEA 10130408en
PubMed Hypericum
Kompas (Dutch) hypericum extract
Wikipedia St John's wort

Switch medication from agomelatine to hypericum.

Nietinrijdenbord.png Stop agomelatine
  • Day 1: Stop agomelatine.
  • Day 1: Stop agomelatine.
  • Agomelatine can be stopped abruptly for every dosage.[1]
Eenrichtingbord.png Start hypericum
  • Day 2: Start administration of hypericum in a dosage of 300 mg three times a day (900 mg/day).
Infobord.png More information
  • No wash-out period is necessary.
  • Hypericum induces the metabolism of agomelatine via CYP1A2.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.